Showing results (1051-1060 of 6,955) with videos related to
Sort By:
Pageof 696
Journal of Clinical Pharmacology|June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignanciesTae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.Journal of Clinical Pharmacology|June 19, 2013
Population pharmacokinetic modeling and dosing simulations of nitrogen-scavenging compounds: disposition of glycerol phenylbutyrate and sodium phenylbutyrate in adult and pediatric patients with urea cycle disordersJon P R Monteleone, M Mokhtarani, G A Diaz, et al.Journal of Clinical Pharmacology|February 6, 2013
Clopidogrel, CYP2C19, and a Black BoxNeville F Ford, Dirk TaubertJournal of Clinical Pharmacology|February 6, 2013
A decision-analysis tool for benefit-risk assessment of nonprescription drugsEric P Brass, Ragnar Lofstedt, Ortwin RennJournal of Clinical Pharmacology|February 6, 2013
Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugsIchiro Ieiri, Shyohei Tsunemitsu, Kazuya Maeda, et al.Journal of Clinical Pharmacology|July 13, 2013
Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumorsCathrine L Denton, Elisabeth Minthorn, Stanley W Carson, et al.Journal of Clinical Pharmacology|July 23, 2013
Person-centric clinical trials: an opportunity for the good clinical practice (GCP)-practice-based research networkFrederick A Curro, Dennis A Robbins, Michael L Millenson, et al.Journal of Clinical Pharmacology|July 24, 2013
A modified grapefruit juice eliminates two compound classes as major mediators of the grapefruit juice-fexofenadine interaction: an in vitro-in vivo "connect"Christina S Won, Tian Lan, Karen M Vandermolen, et al.Journal of Clinical Pharmacology|July 30, 2013
Evaluation of the effects of food on the single-dose pharmacokinetics of trametinib, a first-in-class MEK inhibitor, in patients with cancerDonna S Cox, Kyri Papadopoulos, Lei Fang, et al.Journal of Clinical Pharmacology|August 1, 1990
The influence of pentoxifylline and torbafylline on muscle blood flow in animals with peripheral arterial insufficiencyR F Dinn, H T Yang, R L TerjungPageof 696